I-Helio Health, inkampani yokhathalelo lwempilo eqhutywa yi-AI egxile ekurhwebeni iimvavanyo zokubona umhlaza kwangethuba kwigazi elilula, namhlanje ibhengeze ukuba unxibelelwano lwe-Hepatology lupapashe iziphumo ezilungileyo ezivela kuphononongo lwe-ENCORE oluqinisekisa ukusebenza okuqinileyo kwekliniki ye-HelioLiver ekuboneni ubukho be-hepatocellular carcinoma (HCC) , uhlobo oluqhelekileyo lwesifo somhlaza wesibindi kunye nomhlaza wesixhenxe oqhelekileyo emhlabeni wonke kodwa okwesibini ekufeni okunxulumene nomhlaza, ngokuphindaphindiweyo ngenxa yokuxilongwa kwexesha elide.1 Kulo mzekelo, umfama, uphando lweSigaba se-2 se-91, uHelioLiver ubonise ukuchaneka okuphezulu (76) %) kunye novelwano oluphezulu (57%) ekufumaneni inqanaba lokuqala (inqanaba I kunye ne-II) i-HCC, ngokugqithiseleyo ukugqwesa ezinye izixhobo ezifumaneka kwikliniki ezifana ne-AFP (65%), i-GALAD (47%), kunye ne-ultrasound (2,3%). I-85 Xa uqwalasela i-HCC iyonke, i-HelioLiver yenze kwi-91% ye-sensitivity kunye ne-2% efanayo.XNUMX
| Iimvavanyo zokuxilonga ze-HCC | Inqanaba lokuqala (I + II) Uvakalelo | Ubuntununtunu bebonke |
| HelioLiver2 | 76% | 85% |
| AFP (≥ 20 ng/mL)2 | 57% | 62% |
| Inqaku le-GALAD (≥ -0.63)2 | 65% | 75% |
| omoya3 | 47% | 84% |
| Qaphela: Itheyibhile ibonisa uvakalelo lwe-HelioLiver kwi-91% ethile2 | ||
| 2 ULin N, kunye nabanye. 2021. | ||
| 3 UTzartzeva K, et al. 2018. |
I-Helio yavelisa iqonga layo lokulandelelana kwesizukulwana esilandelayo, i-ECLIPSETM, ukuchonga iithagethi ze-77 ze-methylation kwii-genes ze-28. Ezi mpawu ze-DNA zisebenza ngokudibanisa ne-serum HCC iiprotheyini ze-AFP, i-AFP-L3%, kunye ne-DCP yokuphucula i-algorithm ye-multi-analyte.
• Indawo ephantsi kophawu lokusebenza (i-AUROC) ye-HelioLiver yayiyi-0.944, ibonisa isakhono esingcono kakhulu sokuxela kwangaphambili kunezinye iimvavanyo.
• Kwi-fixed specificity ye-87.5%, i-HelioLiver ifumene i-87% yobuntununtunu kwi-HCC yasekuqaleni kunye ne-90% yobuntununtunu jikelele.
• I-10 ye-28 yezakhi zofuzo ezisetyenziswe kuvavanyo lwe-HelioLiver zifunyenwe zibandakanyeka ngokuthe ngqo kwiindlela ze-molecular ezaziwa ukuba zibandakanyeke kwi-HCC pathogenesis ngelixa enye kuphela ye-497 ephandwayo kodwa engakhethwanga i-gene ye-XNUMX idibene neendlela ezifanayo, ebonisa ukuba abamakishi kwi-HelioLiver bangaphezulu. ngokwebhayoloji ibalulekile kunovavanyo olusebenzisa ezi zezinye iijini.
I-Hepatology Communications yijenali esemthethweni yokufikelela kwi-open, i-peer-reviewed ye-American Association for the Study of Liver Diseases (AASLD), ezinikele ekuhanjisweni ngokukhawuleza kophando oluphezulu kwi-hepatology. I-AASLD ngowona mbutho uhlonitshwayo wemigaqo yezonyango kwizifo zesibindi eUnited States.
I-HelioLiver iphantsi kovavanyo olongezelelweyo njengenxalenye ye-Helio's pivotal, i-biomarker study prospective, i-CLiMB (NCT03694600), apho ukusebenza kovavanyo kuya kufaniswa ngokuthe ngqo ne-ultrasound usebenzisa i-MRI ye-multi-phasic njengomgangatho wokunyamekela ukuxilongwa kwe-HCC.
INTO ONOKUYITHATHA KWELI NQAKU:
- Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver’s strong clinical performance in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most common cancer worldwide but the second in cancer-related mortality, often due to late diagnosis.
- 10 of the 28 genes used in the HelioLiver test were found to be directly involved in molecular pathways known to be implicated in HCC pathogenesis while only one of the investigated but unselected 497 genes met the same criteria, suggesting that the markers in HelioLiver are more biologically relevant than tests that utilize these other genes.
- I-HelioLiver iphantsi kovavanyo olongezelelweyo njengenxalenye ye-Helio's pivotal, i-biomarker study prospective, i-CLiMB (NCT03694600), apho ukusebenza kovavanyo kuya kufaniswa ngokuthe ngqo ne-ultrasound usebenzisa i-MRI ye-multi-phasic njengomgangatho wokunyamekela ukuxilongwa kwe-HCC.
